Core Viewpoint - Genting New Year (01952) has seen a stock price increase of over 4%, currently trading at 45.8 HKD, with a transaction volume of 172 million HKD, following the announcement of two strategic cooperation agreements with Haisen Biopharmaceutical [1] Group 1: Strategic Agreements - Genting New Year’s wholly-owned subsidiary, Genting New Year Pharmaceutical Technology, has signed two strategic cooperation agreements with Haisen Biopharmaceutical [1] - Under the commercialization service agreement, Genting New Year Pharmaceutical Technology will leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] Group 2: Licensing Agreement - The licensing agreement grants Genting New Year Pharmaceutical Technology exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China, enhancing its late-stage pipeline [1] - According to the licensing agreement, Genting New Year Pharmaceutical Technology will make an initial payment of approximately 205 million CNY, with potential development and regulatory milestone payments not exceeding 212 million CNY, and potential sales milestone payments not exceeding 1.977 billion CNY, along with potential royalties based on net sales [1]

Core Viewpoint - Genting New Year (01952) saw a significant increase of over 4% in its stock price, attributed to the announcement of two strategic cooperation agreements with Haisen Biopharmaceutical Co., Ltd. [1] Group 1: Strategic Cooperation Agreements - Genting New Year’s wholly-owned subsidiary, Genting New Year Pharmaceutical Technology Co., Ltd., signed two strategic cooperation agreements with Haisen Biopharmaceutical [1] - Under the commercialization service agreement, Genting New Year Pharmaceutical Technology will leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] Group 2: Licensing Agreement - The licensing agreement grants Genting New Year Pharmaceutical Technology exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China, enhancing its late-stage pipeline [1] - Genting New Year Pharmaceutical Technology will make an initial payment of approximately 205 million yuan, with potential development and regulatory milestone payments not exceeding 212 million yuan, and potential sales milestone payments not exceeding 1.977 billion yuan, along with royalties based on net sales [1]

Group 1 - The core viewpoint of the news is that CloudTop New Horizon has signed two strategic cooperation agreements with Haisen Biopharmaceutical, which will enhance operational efficiency and commercial capabilities in the cardiovascular disease sector [1][2] - The commercialization service agreement allows CloudTop New Horizon to provide services for six mature products from Haisen Biopharmaceutical, with service fees ranging from 20% to 55% of the quarterly net sales [1] - The annual transaction caps for Haisen Biopharmaceutical are set at RMB 560 million for 2026, RMB 616 million for 2027, and RMB 677 million for 2028 [1] Group 2 - The licensing agreement grants CloudTop New Horizon exclusive rights to develop, register, and commercialize Lerodalcibep in Greater China, enhancing its late-stage pipeline [2] - An initial payment of approximately RMB 205 million will be made by CloudTop New Horizon, along with potential milestone payments totaling up to RMB 2.12 billion for development and regulatory milestones, and up to RMB 19.77 billion for sales milestones [2] - Lerodalcibep is a third-generation PCSK9 inhibitor developed by LIB Therapeutics, aimed at lowering LDL-C levels in patients with high cholesterol [2]

Market Performance - The Hong Kong stock market opened higher and experienced a rebound, with the Hang Seng Index rising by 1.36% to 25,878.49 points, the Hang Seng Tech Index increasing by 1.45% to 5,614.94 points, the National Enterprises Index up by 1.17% to 9,038.54 points, and the Red Chip Index gaining 0.72% to 4,132.23 points [1] Sector Performance - Major technology stocks generally rose, with Alibaba up by 1.2%, Tencent Holdings increasing by 1%, JD.com rising by 0.7%, Xiaomi up by 2.7%, NetEase increasing by 2.19%, Meituan rising by 1.97%, Kuaishou up by 1.35%, and Bilibili increasing by 0.93% [1] - Power equipment stocks surged, with Dongfang Electric and Shanghai Electric both rising over 7%, and Northeast Electric increasing by over 5% [1] - Gold stocks saw significant gains, with Zijin Mining rising by over 3% [1] - New consumption concept stocks generally rose, with Cha Bai Dao increasing by over 4% and Guoquan rising by over 3% [1] - Consumer electronics stocks, which were strong yesterday, declined, with most semiconductor stocks experiencing a drop [1] Company News - Hong Kong Technology Exploration (01137.HK) reported a total merchandise transaction value of HKD 636 million in November, a year-on-year decrease of 7.4% [2] - BOE Technology Group (00710.HK) signed a total product processing agreement with BOE in Vietnam [3] - China Galaxy (06881.HK) completed the issuance of a short-term corporate bond worth 4 billion yuan [5] - Cloudy Technology (02670.HK) plans to establish a joint venture focusing on innovative robotic solutions [6] - Nocera Biopharma (09969) received approval for the use of Entrectinib in treating adult and adolescent solid tumors with NTRK fusion genes in China [7] - Peijia Medical-B (09996) received approval from the National Medical Products Administration for the registration application of the TaurusTrio transcatheter aortic valve system [8] - China Antibody-B (03681) had its new drug research application accepted by the National Medical Products Administration [9] - Hengyi Holdings (01894.HK) plans to conduct capital restructuring and fundraising activities [10] Institutional Insights - GF Securities noted that the Hong Kong stock market is more sensitive to external risks, with potential rebound points to watch in mid to late December and early January [11] - Dongwu Securities believes the market is still in a left-side phase and that a rebound requires further waiting [11] - Everbright Securities indicated that while there is significant room for the index to rise compared to previous bull markets, the duration of the bull market may be more important than the magnitude of the increase [11] - Guoxin Securities stated that the recent adjustments in the Hong Kong market could open up space for a market rise in 2026, with over 110 billion yuan of net inflow from southbound funds in November [11] Industry Trends - Ping An Securities highlighted the growing importance of the ice and snow economy, which includes ice and snow sports, tourism, equipment, and culture, as a new economic growth point [12] - The ice and snow industry is experiencing rapid growth, with recommendations to focus on brands with marginal improvements and stable dividend-paying leading companies, specifically mentioning Anta Sports, Bosideng, and Sanfu Outdoor [12]

Market Overview - The Hong Kong stock market opened higher on December 12, with the Hang Seng Index rising by 230.9 points, an increase of 0.9% to 25,761.41 points [1] - The Hang Seng Tech Index increased by 56.56 points, up 1.02% to 5,591.15 points [1] - The National Enterprises Index rose by 78.78 points, a gain of 0.88% to 9,013.06 points [1] - The Red Chip Index climbed by 17.19 points, up 0.42% to 4,119.82 points [1] - Technology stocks saw broad gains, with companies like NetEase, Alibaba, Xiaomi, Lenovo, Tencent, and Kuaishou rising over 1% [1] - Gold stocks also performed well, with China National Gold International increasing by over 4% [1] - Power equipment stocks opened higher, with Dongfang Electric rising by over 2% [1] - New consumption concept stocks were active, with Hu Shang Ayi increasing by over 1% [1] - The lithium battery sector opened higher, with CATL rising nearly 3%, and Ganfeng Lithium and Tianqi Lithium both increasing by over 2% [1] Company News - Hong Kong Technology Exploration (01137.HK) reported a total merchandise transaction value of HKD 636 million in November, a year-on-year decline of 7.4% [2] - BOE Technology Group (00710.HK) signed a total product processing agreement with BOE in Vietnam [3] - China Merchants Securities (06099.HK) was approved to issue company bonds not exceeding RMB 40 billion [4] - China Galaxy (06881.HK) completed the issuance of short-term company bonds amounting to RMB 4 billion [5] - Cloudwalk Technology (02670.HK) plans to establish a joint venture focusing on innovative robotic solutions [6] - Innovent Biologics (09969) received approval for the use of Selpercatinib in treating adult and adolescent patients with NTRK fusion gene solid tumors in China [7] - Peijia Medical-B (09996) received approval from the National Medical Products Administration for the registration application of the TaurusTrio transcatheter aortic valve system [8] - China Antibody-B (03681) had its new drug research application accepted by the National Medical Products Administration [9] - Hengyi Holdings (01894.HK) plans to undergo capital restructuring and fundraising activities [10] Institutional Insights - GF Securities noted that the Hong Kong stock market is more sensitive to external risks, with uncertainties regarding the Federal Reserve's future interest rate cuts and a peak in lock-up stock releases in December, which may lead to liquidity shocks [11] - Dongwu Securities believes that the Hong Kong stock market is still in a left-side phase, and a rebound will require more time [11] - Ping An Securities highlighted the growing importance of the ice and snow economy, which encompasses ice and snow sports, tourism, equipment, and culture, as a new economic growth point [11] - The ice and snow industry is experiencing rapid growth, and companies like Anta Sports, Bosideng, and Sanfu Outdoor are recommended for investment due to their improving margins and stable dividend yields [11] Industry Trends - Western Securities reported that since the end of 2024, the bidding prices for wind turbine manufacturers have shown a continuous upward trend due to self-discipline among manufacturers and changes in bidding rules [12] - The average bidding price for onshore wind turbines in January-October 2025 was RMB 1,618 per kW, a year-on-year increase of 6.86% [12] - The average bidding price for onshore wind turbines (including towers) was RMB 2,096 per kW, a year-on-year increase of 9.78% [12] - The demand for wind turbines in overseas markets is strong, with companies like Goldwind and Envision Energy seeing significant increases in overseas order volumes [12]

Group 1: Industry Developments - Jiangsu Province has officially released its 15th Five-Year Plan, emphasizing the enhancement of industries such as biomedicine, new generation information technology, and high-end equipment, aiming to cultivate strategic emerging industry clusters with international competitiveness [1] - The global first CDK2/4/6 inhibitor, Kimosir, developed by China National Pharmaceutical Group's subsidiary, has been approved for marketing, marking a significant advancement in targeted therapy for breast cancer in China [1] - The innovative drug, Simoziran, developed by Shanghai Pharmaceuticals, has been approved for the treatment of primary hypertension, representing a new addition to the hypertension treatment market [2] Group 2: Company Announcements - Health元 has received a drug registration certificate for its innovative anti-influenza drug, Marpacisavir, which is effective for treating influenza A and B in adolescents and adults, showcasing significant advantages in efficacy and safety [3] - Baijun Medical's subsidiary has received approval for its collagen implant product, the first of its kind in China for improving facial smoothness, highlighting the company's innovation in the collagen field [4] - Innovent Biologics has announced the approval of its next-generation TRK inhibitor, Zoltritinib, for treating adult and adolescent patients with NTRK fusion gene solid tumors, marking a milestone in China's oncology market [5] Group 3: Market Movements - Saili Medical has reported a reduction in shareholding by Shanghai Anze Private Equity Fund to 5.00%, indicating a strategic shift in investment [6][7] - Newnow has submitted an application for H-share listing on the Hong Kong Stock Exchange, reflecting the trend of innovative pharmaceutical companies seeking dual listings [8] - Yunding New Medicine has entered into strategic cooperation with Haishen Biopharmaceuticals, enhancing its commercialization capabilities in the cardiovascular field through service and licensing agreements [9]

Group 1 - Jin Cheng Pharmaceutical's chairman Zhao Yeqing resigned following an administrative penalty from the China Securities Regulatory Commission (CSRC) for stock manipulation, revealing governance issues within the company [1] - Zhao Yeqing and two others were fined 3 million yuan, with Zhao facing a 4-year market ban and Wang Zhen a 3-year ban [1] - The incident may impact investor confidence in the short term, necessitating attention to the new management's election and compliance rectification efforts [1] Group 2 - Stone Pharmaceutical Innovation, a spin-off from Stone Pharmaceutical Group, submitted a prospectus for a Hong Kong IPO, focusing on biopharmaceuticals and health products [2] - Despite anticipated performance pressure in 2024, the company has a strong growth outlook in its biopharmaceutical business and a rich R&D pipeline [2] - The IPO aims to leverage the Hong Kong market for financing, with long-term focus on innovation and profitability improvement [2] Group 3 - Junshi Biosciences filed for an IPO in Hong Kong, highlighting its core product GC101, a novel TIL therapy that does not require intensive chemotherapy or IL-2 administration [3] - GC101 is positioned to be the first TIL therapy approved in China, offering a differentiated advantage in solid tumor treatment [3] - The commercialization model for GC101 remains unproven, and the competitive landscape for TIL therapies is intensifying, necessitating close monitoring of clinical data and post-IPO development [3] Group 4 - Innovent Biologics announced the approval of its new generation TRK inhibitor, Icotinib (ICP-723), by the National Medical Products Administration (NMPA) in China [4] - This marks the first domestically developed new generation TRK inhibitor approved for use in adult and adolescent patients with NTRK fusion gene solid tumors [4] - Icotinib demonstrates superior efficacy over first-generation TRK inhibitors, with strong brain penetration and good overall safety, providing convenience for patients with its oral administration [4] Group 5 - Yunding New Medicine announced strategic agreements with Haisen Biopharmaceutical, including a commercialization service agreement and a licensing agreement [5] - These agreements are expected to create significant financial and strategic synergies, enhancing operational efficiency and commercial capabilities across the product lifecycle [5] - The collaboration aims to strengthen Yunding's cardiovascular pipeline, aligning with growth trends in the sector and potentially opening long-term growth opportunities [5]

Group 1 - Jin Cheng Pharmaceutical's actual controller received an administrative penalty from the China Securities Regulatory Commission (CSRC) for stock manipulation, leading to the resignation of Chairman Zhao Yeqing and exposing governance issues within the company [1] - Zhao Yeqing, Wang Zhen, and Liu Feng were fined a total of 3 million yuan, with Zhao facing a 4-year market ban and Wang a 3-year ban [1] Group 2 - Stone Pharmaceutical Innovation, a spin-off from Stone Pharmaceutical Group, submitted its prospectus to the Hong Kong Stock Exchange for a main board listing, focusing on biopharmaceuticals and health products [2] - Despite facing performance pressure in 2024, the company has a strong growth potential in its biopharmaceutical business and a rich R&D pipeline, aiming to leverage the Hong Kong market for financing [2] Group 3 - JunSai Bio submitted its prospectus to the Hong Kong Stock Exchange, highlighting its core product GC101, a novel tumor-infiltrating lymphocyte (TIL) therapy that does not require intensive chemotherapy or IL-2 administration [3] - GC101 has the potential to be the first approved TIL therapy in China, but its commercialization model remains unproven amid increasing competition in the TIL therapy space [3] Group 4 - Innovent Biologics announced that its new generation TRK inhibitor, Iruvotrib, received approval from the National Medical Products Administration (NMPA) for treating adult and adolescent patients with NTRK fusion gene-positive solid tumors [4] - This approval marks the first domestically developed new generation TRK inhibitor in China, offering improved efficacy and safety compared to first-generation TRK inhibitors [4] Group 5 - Yunding New Medicine announced strategic cooperation agreements with Haisen Biopharmaceutical, including a commercialization service agreement and a licensing agreement, aimed at enhancing operational efficiency and commercial capabilities [5] - These agreements are expected to strengthen Yunding's commercialization capabilities and expand its cardiovascular pipeline, aligning with growth trends in the sector [5]

Core Insights - CloudTop New Horizon Limited has signed two strategic cooperation agreements with Haisen Biopharmaceutical Co., Ltd, which will enhance operational efficiency and accelerate commercialization capabilities in the cardiovascular disease sector [2][3] Group 1: Strategic Agreements - The commercial service agreement allows CloudTop New Horizon to provide commercialization services for six mature products from Haisen Biopharmaceutical, with service fees ranging from 20% to 55% of quarterly net sales [3] - The annual transaction cap for Haisen Biopharmaceutical is set at CNY 560 million for 2026, CNY 616 million for 2027, and CNY 677 million for 2028 [3] Group 2: Licensing Agreement - The licensing agreement grants CloudTop New Horizon exclusive rights for the clinical development, registration, and commercialization of Lerodalcibep in Greater China, with an initial payment of approximately CNY 205 million [4] - Potential milestone payments could reach up to CNY 2.12 billion for development and regulatory milestones, and CNY 19.77 billion for sales milestones, along with royalties based on net sales [4] Group 3: Product Development and Market Position - CloudTop New Horizon has established a commercial platform focused on high-potential markets, with its flagship product, Naisukang, achieving sales exceeding CNY 1 billion by Q3 2025, prompting an upward revision of revenue expectations [5] - The next major product, Aiqumote, is expected to be approved for market launch in the first half of 2026, contributing to the company's profitability [5] - Recent strategic moves include increasing stakes in XinQiao Biotech and introducing VIS-101, indicating a focus on expanding into new therapeutic areas [5]

Core Insights - CloudTop New Horizon (HKEX: 1952) has signed two strategic cooperation agreements with Haisen Biotech, which are expected to create significant financial and strategic synergies, enhancing the operational efficiency of its commercialization platform and accelerating the commercialization capabilities in the cardiovascular disease sector [1][3] Group 1: Agreements Overview - The commercialization service agreement allows CloudTop New Horizon to provide commercialization services for six mature products from Haisen Biotech, covering critical care, cardiovascular, and metabolic treatment areas, with service fees ranging from 20% to 55% of quarterly net sales [1][2] - The licensing agreement grants CloudTop New Horizon exclusive rights for the further clinical development, registration, and commercialization of Lerodalcibep in Greater China, a third-generation PCSK9 inhibitor [2][3] Group 2: Product and Market Potential - Lerodalcibep offers advantages such as a monthly injection and small volume subcutaneous administration, addressing issues of high dosing frequency and storage convenience, which significantly enhances patient compliance [2][3] - Clinical trials involving over 2,500 patients demonstrate that Lerodalcibep can reduce LDL-C levels by over 60% in cardiovascular disease patients and over 55% in patients with familial hypercholesterolemia [2] - The PCSK9 inhibitor market in China is projected to grow rapidly, with an estimated market size of approximately 3 billion yuan in 2024, reflecting a year-on-year increase of 95%, and expected to reach 10 billion yuan by 2030 [3] Group 3: Strategic Implications - The agreements are expected to solidify CloudTop New Horizon's commercialization foundation in China, enhance market share, and inject core growth drivers into its cardiovascular business [3][4] - The collaboration reflects a strategic shift in the industry, where Chinese innovative pharmaceutical companies are transitioning from single product development to platform and diversified strategies [4]